HUE041851T2 - Neopláziás és/vagy fertõzõ betegségek kezelésére alkalmas biciklusos tetrahidrotiazepinszármazékok - Google Patents

Neopláziás és/vagy fertõzõ betegségek kezelésére alkalmas biciklusos tetrahidrotiazepinszármazékok

Info

Publication number
HUE041851T2
HUE041851T2 HUE16707103A HUE16707103A HUE041851T2 HU E041851 T2 HUE041851 T2 HU E041851T2 HU E16707103 A HUE16707103 A HU E16707103A HU E16707103 A HUE16707103 A HU E16707103A HU E041851 T2 HUE041851 T2 HU E041851T2
Authority
HU
Hungary
Prior art keywords
tetrahydrothiazepine
neoplastic
bicyclic
treatment
infectious diseases
Prior art date
Application number
HUE16707103A
Other languages
English (en)
Inventor
Monika Ermann
Guenther Lametschwandtner
Patricia Leonie Amouzegh
Russell Stuart Craft
Thomas Hanke
Timothy Robin James
Severine Danielle Jones
Hans Loibner
Pui Leng Loke
Ina Sternberger
Anton Stuetz
Roland Wehr
Mark Whittaker
Original Assignee
Apeiron Biologics Ag
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag, Evotec Ag filed Critical Apeiron Biologics Ag
Publication of HUE041851T2 publication Critical patent/HUE041851T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36Seven-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
HUE16707103A 2015-03-02 2016-02-29 Neopláziás és/vagy fertõzõ betegségek kezelésére alkalmas biciklusos tetrahidrotiazepinszármazékok HUE041851T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15157175 2015-03-02

Publications (1)

Publication Number Publication Date
HUE041851T2 true HUE041851T2 (hu) 2019-05-28

Family

ID=52705955

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16707103A HUE041851T2 (hu) 2015-03-02 2016-02-29 Neopláziás és/vagy fertõzõ betegségek kezelésére alkalmas biciklusos tetrahidrotiazepinszármazékok

Country Status (12)

Country Link
US (1) US10472341B2 (hu)
EP (1) EP3265463B1 (hu)
JP (1) JP6727224B2 (hu)
CN (1) CN107889487B (hu)
BR (1) BR112017018643B1 (hu)
CA (1) CA2977588C (hu)
DK (1) DK3265463T3 (hu)
ES (1) ES2720577T3 (hu)
HU (1) HUE041851T2 (hu)
IL (1) IL253999B (hu)
RU (1) RU2730524C2 (hu)
WO (1) WO2016139181A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2563642A (en) * 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
WO2022152097A1 (en) * 2021-01-12 2022-07-21 Chengdu Anticancer Bioscience, Ltd. Fused azepine compounds and their use in the treatment of cancer
CN112876366B (zh) * 2021-01-21 2022-10-04 中国科学院昆明植物研究所 一种帚状异酯素、其制备方法和应用,以及药物组合物
AU2022221124A1 (en) * 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CN113075317A (zh) * 2021-03-24 2021-07-06 日照市市场监管检验检测中心 一种茶叶中赤霉素含量的检测方法
CN117980294A (zh) * 2021-09-01 2024-05-03 海南先声再明医药股份有限公司 泛素特异性蛋白酶1(usp1)抑制剂
WO2023119210A1 (ko) * 2021-12-24 2023-06-29 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033389A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030159A1 (en) 1989-11-22 1991-05-23 Nahed K. Ahmed Anti-cancer drug potentiators
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
ATE242258T1 (de) * 1997-03-14 2003-06-15 Aventis Pharma Gmbh Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
WO2003031376A1 (en) * 2001-10-12 2003-04-17 Aventis Pharmaceuticals Inc. Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
US8962641B2 (en) 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EP3265463A1 (en) 2018-01-10
JP6727224B2 (ja) 2020-07-22
BR112017018643A2 (pt) 2018-04-17
ES2720577T3 (es) 2019-07-23
JP2018508527A (ja) 2018-03-29
DK3265463T3 (en) 2019-03-18
US10472341B2 (en) 2019-11-12
RU2017133983A3 (hu) 2019-09-09
CN107889487B (zh) 2021-09-03
CA2977588C (en) 2023-10-03
CA2977588A1 (en) 2016-09-09
CN107889487A (zh) 2018-04-06
RU2017133983A (ru) 2019-04-02
BR112017018643B1 (pt) 2024-02-27
US20180170888A1 (en) 2018-06-21
EP3265463B1 (en) 2018-12-19
IL253999A0 (en) 2017-10-31
RU2730524C2 (ru) 2020-08-24
IL253999B (en) 2020-09-30
WO2016139181A1 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
IL272820B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL253999B (en) History of tetrahydrothiazepine in cyclics used to treat neoplastic and/or infectious diseases
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
HK1258276A1 (zh) 用於治療hiv的化合物和組合
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
EP3429598A4 (en) COMPOSITIONS AND METHODS FOR TREATING BETA-CATENIN-ASSOCIATED DISEASE OR DISORDERS
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
EP3411122A4 (en) CANCER VACCINES AND TREATMENT METHODS THEREWITH
ZA201903572B (en) Compositions and methods for the treatment of oral infectious diseases
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
EP3518951A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS
EP3283457A4 (en) Compounds and methods for the treatment of neurodegenerative diseases
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION
EP3500579A4 (en) CHROMAN-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR TREATING VIRUS DISEASES
EP3500578A4 (en) HETEROCYCLE SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
PT3166604T (pt) Agentes para o tratamento de doenças infeciosas retrovirais
EP2974726A4 (en) Agent for the prophylaxis and/or treatment of neoplastic diseases
GB201500555D0 (en) Method and device for the treatment of diseases
EP3551636A4 (en) THIENOISOCHINOLINE AND THEIR DERIVATIVES FOR TREATING CANCER
AU2016901682A0 (en) Compositions for the Treatment of Diseases and Conditions
EP3223828A4 (en) Methods for the treatment and prevention of asbestos-related diseases